Press Releases

AdvaMed Announces New Head of Diagnostics Division Zach Rothstein Unanimously Named Executive Director by AdvaMedDX Board

WASHINGTON, D.C. — AdvaMed, the world’s largest trade organization representing medical technology companies and innovators, announced today that the AdvaMedDx Board of Directors unanimously selected Zach Rothstein as AdvaMedDx’s new Executive Director. In this role, which he has been serving in on an interim basis since July 6, 2022, Rothstein will direct the policy, advocacy, communications, and legislative strategy, as well as the operations of AdvaMedDx, which represents more than 70 manufacturers of in vitro diagnostic (IVD) clinical tests in the U.S. and abroad.

“Zach Rothstein has been a vital member of the AdvaMed team for many years, lending his expertise to support our industry in MDUFA negotiations and to put our members at the forefront of digital health and cybersecurity, among many other initiatives,” said AdvaMed President and CEO Scott Whitaker. “The COVID-19 pandemic made it clear to everyone the important role diagnostic companies play in our health care system, and we need a strong leader who can give voice to the needs of our Dx members as we tackle key priorities like the diagnostics regulatory reform. I can think of no one better than Zach to lead our AdvaMedDx efforts in the coming years.”

“Over the course of his tenure as interim AdvaMedDx Executive Director and in his various roles at AdvaMed, Zach has shown he has the breadth of experience, skills, and knowledge to permanently lead AdvaMed’s diagnostics division,” said Norman Schwartz, President, and CEO of Bio-Rad and Chairman of the AdvaMedDx Board of Directors.“On behalf of the AdvaMedDx Board, I welcome Zach to the role and look forward to working with him to represent our diagnostic members.”

“Nothing is more important to me than ensuring the patients we serve every day have access to the high quality and essential diagnostic tests our members provide. As I step into this new role, I look forward to building on our previous successes to advance this mission on behalf of our members,” said Zach Rothstein, the newly appointed Executive Director of AdvaMedDx. “It is an honor to be chosen to lead and oversee AdvaMed’s diagnostic division, and I thank the board for their support.”

Prior to this position, Rothstein served as AdvaMed’s Senior Vice President for Technology and Regulatory Affairs where he led the association’s efforts on digital health, software, cybersecurity and postmarket policy.  Rothstein also participated in all aspects of the MDUFA V negotiation process and served as AdvaMed’s lead coordinator for its COVID-19 Action team. Prior to joining AdvaMed, Zach served as Deputy Senior Counsel for Public Policy at Samsung Electronics, where he was responsible for the company’s medical device and healthcare legal, regulatory and policy issues. Prior to Samsung, Rothstein was an attorney in the FDA and health care practice at the law firm Morgan, Lewis & Bockius LLP. Click here for Rothstein’s full bio

# # #

AdvaMed is the world’s largest medical technology association, representing device, diagnostics, and digital technology manufacturers that are transforming health care through earlier disease detection, less invasive procedures, and more effective treatments.